TA125 Psoriatic arthritis (moderate to severe) - adalimumab: understanding NICE guidance (MS Word format)
The summary of the key recommendations of the technology appraisal on Psoriatic arthritis (moderate to severe) - adalimumab . It is written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets or any other suitable publication.
|
TA125 Psoriatic arthritis (moderate to severe) - adalimumab: understanding NICE guidance (MS Word format)
22 August 2007 (504 Kb 2 mins 26 sec) |
